BiotechTube
Home/Pipeline/Undisclosed Liver-Targeting Program(s)

Undisclosed Liver-Targeting Program(s)

Undisclosed

PreclinicalIND-enabling

Key Facts

Indication
Undisclosed
Phase
Preclinical
Status
IND-enabling
Company
Rigerna

About Rigerna

A clinical-stage Chinese biotech developing siRNA drugs with proprietary delivery platforms for liver and non-liver tissues.

View full company profile

Therapeutic Areas

Genetic DiseasesRare DiseasesChronic Diseases

Other Undisclosed Drugs

DrugCompanyPhase
Preclinical ISAC 1Bolt BiotherapeuticsPreclinical
Preclinical ISAC 2Bolt BiotherapeuticsPreclinical
ART12.11Artelo BiosciencesPreclinical
Novel VaccinesMSDDevelopment
SLS-009Seelos TherapeuticsDiscovery
Technosphere Platform (New Formulations)MannKindDiscovery/Preclinical
Measovir®-based Prophylactic Vaccine (with Unither)OncovitaResearch/Pre-clinical
Internal sdAb Discovery ProgramNanoTag BiotechnologiesDiscovery
NB-701Nerai BiosciencesDiscovery
Undisclosed Therapeutic Program(s)Bright CellClinical Trial (Phase unspecified)
Biosimilars PipelineIntelligent TherapeuticsPre-clinical/Development
Proprietary Therapeutic PipelineExcelsior SciencesDiscovery